← Search & browse all drugs
BLOOD AND BLOOD FORMING ORGANS › ANTIHEMORRHAGICS › VITAMIN K AND OTHER HEMOSTATICS › Other systemic hemostatics
emicizumab
B02BX06
Forms & Strengths
- Injection: 30 mg/mL, 60 mg/0.4 mL, 105 mg/0.7 mL, 150 mg/mL, 300 mg/2 mL solution in single-dose vials
Adult Dosing
- Loading dose: 3 mg/kg subcutaneously once weekly for the first 4 weeks
- Maintenance dose: 1.5 mg/kg once weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks
Pediatric Dosing
- Loading dose: 3 mg/kg subcutaneously once weekly for the first 4 weeks (all ages)
- Maintenance dose: 1.5 mg/kg once weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks (all ages)
Indications
- Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A with or without factor VIII inhibitors
Mechanism of Action
- Bispecific factor IXa- and factor X-directed antibody that bridges activated factor IX and factor X, restoring the function of missing activated factor VIII necessary for effective hemostasis
Contraindications
- Hypersensitivity to emicizumab or any of its excipients
- Concurrent use with activated prothrombin complex concentrate (aPCC/FEIBA) for prophylaxis or breakthrough bleeding management
Adverse Reactions
- Injection site reactions
- Headache
- Arthralgia
- Thromboembolic events (with concomitant aPCC use)
- Thrombotic microangiopathy (with concomitant aPCC use)
- Pyrexia
Drug Interactions
- Activated prothrombin complex concentrates (aPCC): Risk of severe thrombosis and thrombotic microangiopathy when used concurrently or within 24 hours of stopping emicizumab
- Emicizumab interferes with aPTT-based coagulation assays, including one-stage factor VIII clotting assays
Curated Content: Needs Vetting Before Put to Clinical Use